CN112437682B - 抗因子XII/XIIa抗体和其用途 - Google Patents

抗因子XII/XIIa抗体和其用途 Download PDF

Info

Publication number
CN112437682B
CN112437682B CN201980046743.3A CN201980046743A CN112437682B CN 112437682 B CN112437682 B CN 112437682B CN 201980046743 A CN201980046743 A CN 201980046743A CN 112437682 B CN112437682 B CN 112437682B
Authority
CN
China
Prior art keywords
antibody
fxii
antibodies
antigen
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980046743.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112437682A (zh
Inventor
D·夏洛索恩
L·C·莫顿
L·米特瑙尔
K·莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN112437682A publication Critical patent/CN112437682A/zh
Application granted granted Critical
Publication of CN112437682B publication Critical patent/CN112437682B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F3/00—Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements
    • H03F3/45—Differential amplifiers
    • H03F3/45071—Differential amplifiers with semiconductor devices only
    • H03F3/45076—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier
    • H03F3/45475—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier using IC blocks as the active amplifying circuit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2203/00—Indexing scheme relating to amplifiers with only discharge tubes or only semiconductor devices as amplifying elements covered by H03F3/00
    • H03F2203/45—Indexing scheme relating to differential amplifiers
    • H03F2203/45444—Indexing scheme relating to differential amplifiers the CMCL comprising a sample and hold circuit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Power Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Amplifiers (AREA)
CN201980046743.3A 2018-06-19 2019-06-19 抗因子XII/XIIa抗体和其用途 Active CN112437682B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687144P 2018-06-19 2018-06-19
US62/687,144 2018-06-19
PCT/US2019/037865 WO2019246176A1 (en) 2018-06-19 2019-06-19 Anti-factor xii/xiia antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN112437682A CN112437682A (zh) 2021-03-02
CN112437682B true CN112437682B (zh) 2024-11-05

Family

ID=67263076

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980046743.3A Active CN112437682B (zh) 2018-06-19 2019-06-19 抗因子XII/XIIa抗体和其用途

Country Status (12)

Country Link
US (1) US12068729B2 (https=)
EP (1) EP3810270A1 (https=)
JP (2) JP7634993B2 (https=)
KR (1) KR20210022650A (https=)
CN (1) CN112437682B (https=)
AU (1) AU2019288299B2 (https=)
CA (1) CA3104470A1 (https=)
EA (1) EA202190056A1 (https=)
IL (1) IL279529A (https=)
MA (1) MA52966A (https=)
MX (1) MX2020013894A (https=)
WO (1) WO2019246176A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240352150A2 (en) * 2020-06-16 2024-10-24 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
JP2023531315A (ja) * 2020-07-03 2023-07-21 シーエスエル・イノベーション・プロプライエタリー・リミテッド 第ｘｉｉ因子抗原結合タンパク質の高濃度製剤
EP4729546A1 (en) * 2023-06-16 2026-04-22 Jiangsu BioJeTay Biotechnology Co., Ltd. Antibody specifically recognizing factor xiia and use thereof
IL325613A (en) * 2023-07-19 2026-02-01 Regeneron Pharma Antibodies against factor xii/xiia and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017258A1 (en) * 1990-05-10 1991-11-14 Cetus Corporation Inhibitors of factor xii activation and applications thereof
WO2013014092A1 (en) * 2011-07-22 2013-01-31 Csl Behring Gmbh Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses
WO2013089493A1 (ko) * 2011-12-16 2013-06-20 주식회사 삼양바이오팜 유착방지용 조성물, 이를 포함하는 유착방지기능을 갖는 수술용 메쉬 복합체 및 이의 제조 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6891394B1 (en) * 2002-06-04 2005-05-10 Actel Corporation Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers
US7378867B1 (en) * 2002-06-04 2008-05-27 Actel Corporation Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CA2591786C (en) 2004-12-23 2013-07-16 Bernhard Nieswandt Prevention of thrombus formation and/or stabilization
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US7541838B2 (en) * 2007-03-27 2009-06-02 Intel Corporation Transmitter swing control circuit and method
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
EP2384766A1 (en) * 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel antibody to a carbonic anhydrase
CN103415301A (zh) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
TWI613215B (zh) * 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
WO2014089493A1 (en) * 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
KR20150139089A (ko) * 2014-06-02 2015-12-11 한국전자통신연구원 멀티플라이어 및 다중 입력 증폭기를 포함하는 전류-전압 변환 증폭 회로
US10259874B2 (en) * 2014-10-27 2019-04-16 Agency For Science, Technology And Research Anti-TIM-3 antibodies
CN111919424A (zh) * 2018-07-02 2020-11-10 拉姆伯斯公司 利用早期高阶符号检测用于判决反馈均衡的方法和电路

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017258A1 (en) * 1990-05-10 1991-11-14 Cetus Corporation Inhibitors of factor xii activation and applications thereof
WO2013014092A1 (en) * 2011-07-22 2013-01-31 Csl Behring Gmbh Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses
WO2013089493A1 (ko) * 2011-12-16 2013-06-20 주식회사 삼양바이오팜 유착방지용 조성물, 이를 포함하는 유착방지기능을 갖는 수술용 메쉬 복합체 및 이의 제조 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Extracorporeal Circulation Without Increasing Bleeding Risk;Magnus Larsson等;《ScienceTranslationalMedicine》;第6卷(第222期);全文 *
A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C1 esterase inhibitor;M P Esnouf等;《Thromb Haemost 》;第83卷(第6期);874-881 *
Robin A. Pixley等.A MonoclonaAl ntibody Recognizing an Icosapeptide Sequence in the Heavy Chain of Human Factor XI1 Inhibits Surface-catalyzed Activatio.1987,第262卷(第21期),全文. *

Also Published As

Publication number Publication date
CA3104470A1 (en) 2019-12-26
US12068729B2 (en) 2024-08-20
JP2024116399A (ja) 2024-08-27
JP2021527424A (ja) 2021-10-14
EP3810270A1 (en) 2021-04-28
KR20210022650A (ko) 2021-03-03
MX2020013894A (es) 2021-05-27
AU2019288299B2 (en) 2026-02-05
CN112437682A (zh) 2021-03-02
JP7634993B2 (ja) 2025-02-25
EA202190056A1 (ru) 2021-05-28
WO2019246176A8 (en) 2020-10-08
WO2019246176A1 (en) 2019-12-26
MA52966A (fr) 2021-04-28
IL279529A (en) 2021-01-31
US20210203292A1 (en) 2021-07-01
AU2019288299A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
JP7368543B2 (ja) 抗ｃ５抗体及びそれらの使用
JP2024116399A (ja) 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
JP2024503784A (ja) Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質
US12304969B2 (en) Factor XI A2 domain-binding antibodies and methods of use thereof
JP7807238B2 (ja) 骨形成タンパク質６に対するヒト抗体
US20240190996A1 (en) Factor xi catalytic domain-binding antibodies and methods of use thereof
CN121568964A (zh) 抗因子XII/XIIa抗体及其用途
US12612452B2 (en) Human antibodies to bone morphogenetic protein 6
EA048528B1 (ru) АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
EA052707B1 (ru) Антитела, связывающие домен a2 фактора xi, и способы их использования
EP2964670B1 (en) Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
EA041355B1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА К ТОКСИНУ ГЕМОЛИЗИНУ А S.aureus
EA039858B1 (ru) Антитела против c5 и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant